Designing Better Mitochondria-Targeting Peptides: How Amino Acid Changes Affect Drug Potency
A systematic comparison of mitochondria-targeted tetrapeptides found that a tryptophan-containing analog outperformed the clinical compound SS-31 in protecting cells from mitochondrial stress.
Quick Facts
What This Study Found
Researchers conducted the first detailed structure-activity analysis of mitochondria-targeted tetrapeptides — the class that includes SS-31 (elamipretide). They compared four peptide analogs that differ in their aromatic amino acid composition and sequence order. Using NMR and molecular dynamics, they produced the first structural models of this compound class, revealing that all analogs except SS-31 form compact reverse turn conformations when bound to membranes.
All four peptides bound cardiolipin-containing membranes (a key mitochondrial lipid), reached mitochondria in cell culture, and showed pharmacological activity in stress models. However, they differed significantly in membrane interactions, effects on membrane surface charge, and ability to restore mitochondrial function. The tryptophan-containing analog SPN10 showed the strongest membrane effects and greatest cell protection, suggesting tryptophan side chains may be optimal for this class of therapeutics.
Key Numbers
4 tetrapeptide analogs compared · First NMR structural models for this class · SPN10 (tryptophan analog) showed greatest efficacy · All 4 peptides targeted mitochondria · Cardiolipin binding confirmed for all analogs
How They Did This
Four tetrapeptide analogs with alternating cationic and aromatic residues were synthesized and compared. Structural characterization used Nuclear Magnetic Resonance (NMR) spectroscopy and molecular dynamics simulations to model peptide conformations in membrane-bound states. Membrane binding studies measured interactions with cardiolipin-containing model membranes. Cell culture assays in mammalian cells assessed mitochondrial targeting, cell permeability, mitochondrial membrane potential, ATP levels, and cell survival under serum withdrawal stress conditions.
Why This Research Matters
SS-31 (elamipretide) is the most advanced mitochondria-targeted peptide therapeutic, currently in clinical trials for heart failure and mitochondrial diseases. But scientists haven't fully understood how these peptides work at a molecular level. This study provides the first structural models and systematic comparison of analogs, establishing a framework for designing more potent next-generation versions. The finding that SPN10 outperformed SS-31 in several measures suggests there's room to improve on the lead clinical compound.
The Bigger Picture
Elamipretide (SS-31) is one of the most closely watched peptide therapeutics in development, with clinical trials for Barth syndrome, heart failure, and mitochondrial myopathies. This structure-activity study is important because it moves the field beyond a single lead compound toward rational design of improved analogs. The finding that modulating membrane electrostatics appears central to the mechanism also helps explain why these peptides work, which has been debated for over a decade.
What This Study Doesn't Tell Us
All experiments were conducted in vitro using model membranes and cell culture — no animal or human studies were included. The serum withdrawal stress model is a simplified representation of mitochondrial dysfunction that may not capture the complexity of mitochondrial diseases in living organisms. Only four analogs were tested, which is a small fraction of the possible sequence space. The study doesn't address in vivo pharmacokinetics, stability, or tissue distribution.
Questions This Raises
- ?Does SPN10's superior in vitro performance translate to better efficacy in animal models of mitochondrial disease?
- ?Could combining the optimal features of multiple analogs create an even more potent mitochondria-targeted peptide?
- ?How do these structural differences affect the peptides' pharmacokinetics and safety profiles in living organisms?
Trust & Context
- Key Stat:
- SPN10 outperformed SS-31 The tryptophan-containing analog showed the strongest membrane effects and greatest cell-protective efficacy among the four peptides tested
- Evidence Grade:
- This is a rigorous in vitro structure-activity study published in eLife with multiple complementary experimental approaches. The evidence is moderate — it provides strong mechanistic insights and comparative data, but all findings need to be validated in animal models and ultimately human studies.
- Study Age:
- Published in 2022. Recent and highly relevant as elamipretide (SS-31) continues through clinical trials. The structure-activity insights may inform next-generation compound design.
- Original Title:
- Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds.
- Published In:
- eLife, 11 (2022)
- Authors:
- Mitchell, Wayne(2), Tamucci, Jeffrey D(2), Ng, Emery L, Liu, Shaoyi, Birk, Alexander V, Szeto, Hazel H, May, Eric R, Alexandrescu, Andrei T, Alder, Nathan N
- Database ID:
- RPEP-06372
Evidence Hierarchy
Frequently Asked Questions
What are mitochondria-targeted peptides and why do they matter?
Mitochondria-targeted peptides are small molecules (usually 4 amino acids) designed to enter cells and specifically reach mitochondria — the organelles that produce energy. When mitochondria malfunction, it contributes to diseases ranging from heart failure to rare genetic conditions to aging itself. SS-31 (elamipretide) is the most advanced of these peptides and is in clinical trials. This study helps scientists understand how to make even better versions.
What makes the SPN10 analog potentially better than SS-31?
SPN10 contains tryptophan amino acids instead of the phenylalanine found in SS-31. This study found that SPN10 had stronger effects on mitochondrial membranes and was better at restoring membrane potential, preserving energy (ATP), and promoting cell survival under stress. The tryptophan's larger aromatic ring system may interact more strongly with cardiolipin, a critical lipid in mitochondrial membranes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-06372APA
Mitchell, Wayne; Tamucci, Jeffrey D; Ng, Emery L; Liu, Shaoyi; Birk, Alexander V; Szeto, Hazel H; May, Eric R; Alexandrescu, Andrei T; Alder, Nathan N. (2022). Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds.. eLife, 11. https://doi.org/10.7554/eLife.75531
MLA
Mitchell, Wayne, et al. "Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds.." eLife, 2022. https://doi.org/10.7554/eLife.75531
RethinkPeptides
RethinkPeptides Research Database. "Structure-activity relationships of mitochondria-targeted te..." RPEP-06372. Retrieved from https://rethinkpeptides.com/research/mitchell-2022-structureactivity-relationships-of-mitochondriatargeted
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.